DENVER -- A sustained-release VEGF inhibitor implant outperformed standard anti-VEGF therapy for maintaining visual acuity in neovascular, or wet, age-related macular degeneration (AMD), showed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results